Key Developments For Nanosphere, Inc.
Nanosphere, Inc. (NSPH.O) (Consolidated Issue listed on NASDAQ Global Market)
Nanosphere, Inc. Announces FDA Clearance To Update Package Insert For Respiratory Virus Assay
Nanosphere, Inc. announced that it has received 510(k) clearance from the FDA to update its package insert for its Verigene Respiratory Virus Nucleic Acid Test on Verigene SP System (RVNATSP) to include reactivity with Influenza A in cultured clinical isolates containing 2009 H1N1 influenza virus.
Nanosphere, Inc. Announces FDA Submission Of 510(k) Documentation For Verigene Cardiac Troponin I Assay
Nanosphere, Inc. announced that it has submitted a 510(k) application to the FDA for its cardiac troponin I test that the Company believes will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.
Nanosphere, Inc. Closes Common Stock Offering
Nanosphere, Inc. announced the closing of its previously announced underwritten public offering of 5,405,000 shares of its common stock at a public offering price of $7.00 per share, including 705,000 shares of common stock issued pursuant to the underwriter's exercise in full of its over-allotment option. Piper Jaffray & Co. acted as the sole manager for the offering. Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately $35.3 million. The Company plans to use the net proceeds from the offering for general corporate purposes and working capital.
Nanosphere, Inc. Announces Northwestern University Study Finds Ultrasensitive Assay Can Predict Recurrence of Prostate Cancer
Nanosphere, Inc. announced that a research team at Northwestern University's International Institute for Nanotechnology found that an ultrasensitive nanoparticle-based assay, 300 times more sensitive than commercial immunoassays, is capable of detecting previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. After the removal of the prostate gland, patients typically have PSA levels that are undetectable when measured by using conventional diagnostic tools, and which can take years to detect recurrent cancer. This ability to easily and quickly detect very low levels of PSA may enable doctors to diagnose men with prostate cancer recurrence years earlier than is currently possible. Nanosphere and Northwestern's International Institute for Nanotechnology are currently engaged in a retrospective study on radical prostatectomy patients and will soon be launching a broad prospective study.
Nanosphere, Inc. Prices Common Stock Offering
Nanosphere, Inc. announced the pricing of its previously announced underwritten public offering of 4,700,000 shares of its common stock at a public offering price of $7.00 per share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 705,000 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. acted as the sole manager for the offering. Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately $30.6 million. If the underwriter exercises its over-allotment option in full, net proceeds from the offering will be approximately $35.3 million. The offering is subject to customary closing conditions and is expected to close on Wednesday, October 21, 2009. The Company plans to use the net proceeds from the offering for general corporate purposes and working capital.
